Cara Therapeutics | CARA - Gross Profit On Sales


Cara Therapeutics reported $2.57M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Assertio Holdings USD 22.24M 970K Jun/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Chugai Pharma JPY 258.74B 25.81B Dec/2025
Cipla INR 39.1B 2.54B Mar/2026
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 63.8M 63.56M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
J&J USD 17.24B 642M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pacira USD 126.64M 15.61M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
RedHill Biopharma USD 584K 0 Jun/2024
Supernus Pharmaceuticals USD 129.36M 34.68M Mar/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024